Product information and disease description Place of product in therapy Disease description Burden of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Economic impact of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma on families

4 evidence topics · 3 sources

Summary: work loss, indirect costs, and family financial exposure

Cholangiocarcinoma imposes measurable work loss and indirect costs on working-age households. In a United States retrospective claims analysis of 1,065 participants with cholangiocarcinoma who had work absence and disability benefits eligibility, mean all-cause days absent per patient per month for illness were 6.0 for intrahepatic and 4.3 for extrahepatic disease, and 12.9% and 6.6% respectively had at least one cholangiocarcinoma-related short-term disability claim. Median indirect costs per patient per month from absenteeism, short-term disability, and long-term disability were $622, $635, and $690 for intrahepatic disease and $304, $589, and $465 for extrahepatic disease. A patient and advocate writing in a disease primer describes declining a first-line clinical trial because insurance would not cover the associated standard-of-care costs and she did not want to put her family in financial distress, and describes travel for trial participation as a source of financial burden.

Economic impact on families: productivity loss and indirect costs

“One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA.” (opens the source at this quote in a new tab)
“Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA.” (opens the source at this quote in a new tab)
“In the absenteeism, short-term disability, and long-term disability cohorts, respectively, mean indirect costs associated with productivity loss contributed to 8.6, 7.2, and 6.7% of the total costs ($11,287, $11,887, and $11,977).” (opens the source at this quote in a new tab)
“This suggests that patients in our analysis are more economically advantaged than the overall population of the United States, many of whom do not have access to paid sick leave or are not provided with insurance by their employers. Thus, our analysis may underestimate the productivity losses within the overall population of the United States.” (opens the source at this quote in a new tab)

Economic impact on families: out-of-pocket exposure and travel for clinical trials

“Unfortunately, my insurance at that time would not cover the standard-of-care costs that go along with being in a clinical trial. I chose not to join the trial because I did not want to put my family in financial distress.” (opens the source at this quote in a new tab)
“Patients most likely will have to travel to be able to participate in a trial and that, in turn, causes other issues, such as financial burden.” (opens the source at this quote in a new tab)

Economic impact on families: household income relative to the cost of oral targeted therapy

“According to the U.S. Census Bureau, the average U.S. household income in 2022 was $105,555, while the median U.S. household income was $74,580. Without private or public health insurance, the kinase inhibitor costs are prohibitive.” (opens the source at this quote in a new tab)